null

Anti-Human IL-2R alpha (CD25) (Basiliximab) - Dylight 488 (IVMB0498)

SKU:
IVMB0498
€1,049
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human IL-2R alpha (CD25) (Basiliximab) - Dylight 488
SKU:IVMB0498
Size:100 µg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:Hu107
Target:CD25
Isotype:Human IgG1κ
Host Species:Human
Reactivity:Human/Rhesus Monkey/Cynomolgus Monkey
Applications:FC
Expression Host:HEK-293 Cells
FC Effector Activity:Active
Synonyms:IL-2-RA; IL2-RA; TAC antigen; p55; CD25
Product Concentration:0.2 mg/ml
Excitation Laser:Blue Laser (493 nm)
Immunogen:Human CD25
Applications and Recommended Usage:FC The suggested concentration for Basiliximab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Antigen Distribution:IL-2Rα is expressed on activated mature T and B lymphocytes, during early stages of thymocytes development, pre-B cells, and in activated CD4+ memory T-lymphocytes.
Formulation:This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Basiliximab. Basiliximab recognizes human CD25. This product is for research use only.
Additional Applications Reported In Literature:IFIHC
Additional Reported Applications For Relevant Conjugates:CyTOFWBB

CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Rα. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects.

Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Storage and Handling:This DyLight 488 conjugate is stable when stored at 2-8°C.Do not freeze.
Research Area:Biosimilars

Related Products